Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

The Finviz API: Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now

Akero Therapeutics Inc.

Contributing Author

Recent Articles by Akero Therapeutics Inc.

Nov-07	Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting 2025 GlobeNewswire
Oct-09	Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion GlobeNewswire
Oct-07	Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting 2025 GlobeNewswire
Aug-28	Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire
Aug-14	Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH GlobeNewswire
Aug-08	Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire
Jun-03	Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference GlobeNewswire
May-28	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-12	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire
May-10	Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 GlobeNewswire
May-09	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 GlobeNewswire
May-09	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine GlobeNewswire
May-09	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 GlobeNewswire
May-07	Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)